Loxoprofen sodium (CS-600) is an effective and oral sodium inhibitor of COX-1 and COX-2 with IC50 of 6.5 and 13.5 μM, respectively. Loxoprofen sodium works by reducing the synthesis of prostaglandins from arachidonic acid. Loxoprofen sodium has anti-inflammatory and antitumor activity and can be used to treat atherosclerosis.

'Loxoprofen sodium, an anti-inflammatory prodrug, is a nonselective COX inhibitor with IC50s of 6.5 and 13.5μM for COX-1 and COX-2 in human whole blood assays, respectively.[1]
Loxoprofen sodium is a non-selective cyclooxygenase inhibitor that is widely used for the research of pain and inflammation caused by chronic and transitory conditions. In addition, LOX sodium can also be converted into an inactive hydroxylated metabolite (OH-LOXs) by cytochrome P450 (CYP).[2]'

"Loxoprofen reduces acetic acid-induced writhing in mice and carrageenan-induced paw edema and LPS-induced fever in rats (ED30s = 20.1, 0.7, and 2.79 mg/kg, respectively).[3]
Loxoprofen sodium (4 mg/kg/day; p.o.; 1 or 8 weeks) reduces atherosclerosis in mice by reducing inflammation[4].
Loxoprofen sodium (60 μg/mL; p.o.; 24 days) suppresses mouse tumor growth by inhibiting VEGF[5]."